Back to journals
Academic Journal

Psyarxiv

19 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 19 psychedelic papers Blossom tracks from Psyarxiv line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Psyarxiv carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

7papers published in 2021

7 published by 2021

Browse papers→

Don't read as the journal's total output: only the 19 of 19 tracked psychedelic papers from Psyarxiv with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Psyarxiv publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
8
Anxiety Disorders
7
PTSD
4
Schizophrenia
3
Microdosing
3
Creativity
3
Addiction & Substance Use
2
Suicidality
2
Other
17

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Psyarxiv cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

MDMA
4
Ayahuasca
4
LSD
4
Psilocybin
4
DMT
1
Ketamine
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Psyarxiv has 19 tracked papers indexed in Blossom (2021–2026) from 64 authors, most often covering MDMA, Ayahuasca and LSD, across Depressive Disorders, Anxiety Disorders and PTSD.

Published Papers

Open Accessindividual

MDMA-Assisted Therapy for Social Anxiety Disorder: A Randomized, Open-label, Wait-list Controlled Trial

This randomised, open-label, wait-list-controlled trial (n=20) found that MDMA-assisted therapy reduced social anxiety symptoms more than waiting for treatment and improved functioning in adults with social anxiety disorder (SAD).

Published
Journal
Psyarxiv
Authors
Luoma, J. B., Lear, M. K., Pilecki, B., Lejeune, J., Yi, K., Chwyl, C., Mehr, S., Sarparast, A., Kennedy, L., Lucas, W., Spata, A., Stauffer, C.
Open Accessindividual

Psychedelic Intimacy: Altered States of Consciousness in Romantic Relationships

Interviews with six young romantic couples who used classic psychedelics together yielded three core themes—navigating anxiety, reshaping practices and encountering bliss—that characterised their shared altered-state experiences. These experiences met interactional intimacy criteria (self‑exposure, positive involvement, shared understanding) but were distinct enough to warrant a novel concept of "psychedelic intimacy" and indicate potential for psychedelic‑assisted couples therapy.

Published
Journal
Psyarxiv
Authors
Neubert, J. J., Anderson, K., Mason, N. L.
Open Accessmeta

A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions

This systematic review of 33 psychedelic clinical trials found pervasive underreporting of psychosocial intervention details — for example, 33% omitted number of sessions, 45% omitted session duration, 42% omitted provider credentials, 52% did not report use of a therapy manual, 67% provided no accessible manual, and 82% did not assess treatment fidelity. Reporting was poorer than in non‑psychedelic trials, and the authors recommend standardised reporting of psychological support and fidelity measures to improve research transparency and treatment outcomes.

Published
Journal
Psyarxiv
Authors
Brennan, C., Kelman, A., Belser, A. B.
Open Accessmeta

Overcoming blinding confounds in psychedelic randomized controlled trials using biomarker driven causal mediation analysis

This commentary (2023) suggests that causal mediation analysis using objective biomarkers could help establish causal pathways between treatment and outcome, providing greater confidence in the efficacy of psychedelic therapies before they are approved as regular medicines. This cautious approach is recommended to avoid potential drawbacks such as expanding indications based on low-quality evidence and unstable efficacy over time.

Published
Journal
Psyarxiv
Authors
Muthukumaraswamy, S.
Open Accessindividual

Effects of ayahuasca on gratitude and relationships with nature: An open-label, naturalistic study

In an open-label naturalistic study of 54 retreat participants, ayahuasca use was associated with significant increases in gratitude, nature relatedness and nature appreciation at one week and one month post-retreat, with weak-to-moderate correlations between these increases and mystical-type experiences and awe but not ego dissolution. The findings suggest ayahuasca-occasioned mystical and awe experiences may lead to personality changes beneficial for mental health and prosocial behaviour, though further research is required.

Published
Journal
Psyarxiv
Authors
Bloesch, E. K., Davis, A. K., Domoff, S. E., Scherr, K., Woolley, J. D., Davoli, C. C., Adams, A. M.
Open Accessindividual

Ayahuasca in the treatment of bipolar disorder with psychotic features-A retrospective case study

This retrospective case study describes a woman with bipolar disorder and psychotic features whose suicidality, dissociation and social isolation markedly improved and were sustained after multiple ayahuasca ceremonies, with corroboration of childhood abuse and ongoing symptom reduction over several years. The report suggests potential therapeutic benefits of ayahuasca for severe traumatisation and bipolar symptoms and situates the case within a brief review of low‑dose ayahuasca and LSD treatment literature.

Published
Journal
Psyarxiv
Authors
Turkia, M.

Quick Facts

Papers Indexed
19
Publisher
Society for the Improvement of Psychological Science
Website
Visit